Disease-Vaccine-Landing-Page/Pneumococcal/vaccine-effectiveness

CAPVAXIVE (PCV21), manufactured by Merck, was approved by the FDA through an accelerated approval process, in June 2024. According to the manufacturer, in adults 50 years and older, PCV21 targets...

The continued emergence of non-vaccine types pneumococcal strains prompted the development of new pneumococcal vaccines. Merck received FDA approval in July 2021 for a 15-valent pneumococcal vaccine, PCV15, for use...

Information on pneumococcal conjugate vaccine efficacy found in the Prevnar 13(PCV13) product insert reports information pertaining to the original PCV vaccine, Prevnar (PCV7). PCV7 was reported to be 100 percent...

The initial pre-licensing clinical trials of a pneumococcal capsular polysaccharide involved a comparison study of the effectiveness of a 6-valent polysaccharide vaccine against a 12-valent polysaccharide vaccine. The study involved...